*June 2023* Rezivertinib (BPI-7711) showed promising clinical central nervous system (CNS) efficacy among patients with advanced non–small cell lung cancer (NSCLC) with EGFR T790M mutation and CNS metastases. The study included individual data from 2 different single-arm, phase 1 (NCT03386955) and phase 2b studies (NCT03812809) to assess the CNS response of rezivertinib…
laurabbook@gmail.comSeptember 29, 2023